Applied Genetic Technologies Corporation

The Applied Genetic Technologies Corporation is a publicly traded (NASDAQ: AGTC)[2] biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida.[3] In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.[4]

Applied Genetic Technologies Corporation
TypePublic company
NASDAQ: AGTC
Russell Microcap Index component
IndustryBiotechnology
FoundedJanuary 19, 1999 (1999-01-19)
HeadquartersAlachua, Florida, United States
Key people
  • Susan B. Washer
  • (President & CEO)
  • William A. Sullivan
  • (CFO)
Revenue
  • US$ 24.19 million
  • (FY JUN 30, 2018)
  • US$ -22.38 million
  • (FY JUN 30, 2018)
  • US$ -21.30 million
  • (FY JUN 30, 2018)
Total assets
  • US$ 118.53 million
  • (FY JUN 30, 2018)
Total equity
  • US$ 99.18 million
  • (FY JUN 30, 2018)
Number of employees
  • 78
  • (FY JUN 30, 2018)
WebsiteAGTC.com
Footnotes / references
[1]

The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis,[5][6] X-linked retinitis pigmentosa,[7] and age-related macular degeneration.[8] The company has six products in various stages of development; as of 2016, none had yet been approved.[9]

In January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC’s deep experience in gene therapy and ophthalmology.[10]

On January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational gene therapy for retinitis pigmentosa.[11] A few weeks later, the company reported interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes.[12] Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including organizations like Foundation for Fighting Blindness and Global Genes.[13]

References
  1. "US SEC: Form 10-K Applied Genetic Technologies Corporation". U.S. Securities and Exchange Commission. September 11, 2018. Retrieved December 1, 2018.
  2. "Applied Genetic Technologies Corporation (AGTC)". NASDAQ.com. Retrieved 4 January 2016.
  3. "Company Overview of Applied Genetic Technologies Corporation". Bloomberg. Retrieved November 15, 2016.
  4. "AGTC Announces New Leadership Appointments". Applied Genetic Technologies Corporation. Retrieved 2020-03-26.
  5. Chen, Angela. "Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments". Wall Street Journal. Retrieved 4 January 2016.
  6. "AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting". Yahoo Finance. Retrieved 4 January 2016.
  7. "Biogen enters eye-treatment arena with AGTC deal". Reuters. 2 July 2015. Retrieved 4 January 2016.
  8. Ballie, Katherine. "Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia". www.upenn.edu. Retrieved 4 January 2016.
  9. "Finding Cures for Visual Disorders l Products". www.agtc.com. Archived from the original on 5 January 2016. Retrieved 4 January 2016.
  10. "Collaborations". agtc.com. Retrieved 2020-03-13.
  11. Lee, Jaimy. "Applied Genetic Technologies' stock rockets on early-stage eye therapy data". MarketWatch. Retrieved 2020-02-25.
  12. "AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia". Applied Genetic Technologies Corporation. Retrieved 2020-03-04.
  13. "Patient Partners". agtc.com. Retrieved 2020-04-02.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.